New COVID-19 nasal spray outperforms current antibody treatments in mice: A single inhaled dose treated or even prevented infection by COVID-19 and its variants - Science Daily

Current antibody treatments block SARS-CoV-2 by binding to one of three binding sites on the spike protein. A new protein-based antiviral binds to all three sites on the spike protein, making it more effective than current therapies. The new therapy also is l…

A new protein-based antiviral nasal spray developed by researchers at Northwestern University, University of Washington and Washington University at St. Louis is being advanced toward Phase I human c… [+5819 chars]

full article...